Mumbai, Jan. 23 -- Contract drug research and manufacturing firm Syngene International Ltd has lowered its full-year revenue guidance from mid-single digit growth to negative 2-3%, as destocking of a single biologics product weighed on its growth for a second consecutive quarter, chief executive and managing director Peter Bains told Mint in an interview on Friday.

"In light of the impact that we're seeing on this single large molecule, we will be adjusting our guidance on revenue, where we had a mid-single digit guidance previously, which will now go to 2-3% negative," he said.

"This single product was the largest commercial product in our manufacturing platform, and its impact has been material, and it is clearly playing through in ou...